The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials

35 Citationer (Scopus)

Abstract

Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan was reviewed. In the intravenous placebo-controlled RCT, lasmiditan doses of 2.5-45 mg were used, and there was a linear association between headache relief (HR) rates and dose levels (P 
OriginalsprogEngelsk
TidsskriftJournal of Headache and Pain
Vol/bind13
Udgave nummer4
Sider (fra-til)271-5
Antal sider5
ISSN1129-2369
DOI
StatusUdgivet - 2012

Fingeraftryk

Dyk ned i forskningsemnerne om 'The 5-HT(1F) receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials'. Sammen danner de et unikt fingeraftryk.

Citationsformater